

Gene Transfer and the Ethics of First-in-Human Research



Gene Transfer and the Ethics of First-in-Human Research

Lost in Translation

Jonathan Kimmelman

McGill University / Biomedical Ethics Unit and Social Studies of Medicine





CAMBRIDGE UNIVERSITY PRESS

Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo, Delhi, Dubai, Tokyo

Cambridge University Press The Edinburgh Building, Cambridge CB2 8RU, UK

Published in the United States of America by Cambridge University Press, New York

www.cambridge.org

Information on this title: www.cambridge.org/9780521690843

© J. Kimmelman 2010

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2010

Printed in the United Kingdom at the University Press, Cambridge

A catalogue record for this publication is available from the British Library

Library of Congress Cataloguing in Publication data

Kimmelman, Jonathan.

Gene transfer and the ethics of first-in-human research: lost in translation / Jonathan Kimmelman.

p. cm.

Includes bibliographical references and index.

ISBN 978-0-521-69084-3 (pbk.) 1. Gene therapy–Moral and ethical aspects.

2. Clinical trials–Moral and ethical aspects. I. Title.

[DNLM: 1. Gene Transfer Techniques-ethics. 2. Human Experimentation-ethics.

3. Public Policy. WB 60 K49g 2010]

RB155.8.K56 2010

615.8'95-dc22 2009029830

ISBN 978-0-521-69084-3 Paperback

Cambridge University Press has no responsibility for the persistence or accurancy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this book to provide accurate and up-to-date information that is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.



For Chichester and Gooch



We grow accustomed to the Dark — When light is put away — As when the Neighbor holds the Lamp To witness her Goodbye —

A Moment – We uncertain step For newness of the night –– Then – fit our Vision to the Dark –– And meet the Road – erect ––

And so of larger – Darkness ––
Those Evenings of the Brain ––
When not a Moon disclose a sign ––
Or Star – come out – within ––

The Bravest – grope a little –– And sometimes hit a Tree Directly in the Forehead –– But as they learn to see ––

Either the Darkness alters —
Or something in the sight
Adjusts itself to Midnight —
And Life steps almost straight.

Emily Dickinson



Contents

Acknowledgments
List of abbreviations

viii x

- 1 Introduction: gene transfer lost in translation 1
- 2 What is gene transfer? 8
- 3 Safety, values, and legitimacy: the protean nature of risk in translational trials 31
- 4 Taming uncertainty: risk and gene-transfer clinical research 51
- 5 Succor or suckers? Benefit, risk, and the therapeutic misconception 72
- 6 Looking backward: a model of value for translational trials 89
- 7 The chasm: the ethics of initiating first-in-human clinical trials 110

- 8 Tropic of cancers: gene transfer in resource-poor settings 132
- 9 Great Expectations and Hard Times: expectation management in gene transfer 153
- 10 Something in the sight adjusts itself: conclusions 178

Epilogue 192 Index 193



Acknowledgments

This book began inauspiciously enough when, newly arrived in Montreal with a very bad haircut and a Ph.D. in molecular genetics, I approached Kathy Glass about post-doctoral studies in bioethics. I am grateful to Kathy for taking a risk by hiring me (first as a post-doc, and later as an assistant professor) and supporting this research.

I also thank Nancy King for her inspiring work in research ethics, as well as her support and critical feedback at key junctures. My colleague Nick King (no relation) provided a fine-grained vetting of this book. Alex London was a ready and more than able intellectual sparring partner throughout the writing process. Rebecca Dresser and Eric Juengst were gratuitously generous for agreeing to read my manuscript.

Numerous other oversubscribed colleagues, friends, and strangers made important contributions. These include: James Anderson, Françoise Baylis, Alberto Cambrosio, Marina Emborg, Dean Fergusson, Abe Fuks, Margaret Lock, Josephine Nalbantoglu, Tim Ramsey, Jason Scott Roberts, Thomas Schlich, Stan Shapiro, Charles Weijer, George Weisz, and Allan Young. I thank the many gene-transfer researchers, clinical investigators, and laboratory scientists (too numerous to name – and many probably preferring anonymity anyway) who graciously and patiently entertained my questions over the years. I also thank my editors at Cambridge, Katie James, Nick Dunton, Matt Davies and John Forder.

I received feedback from many anonymous commentators through peer review of various articles relating to this book. Some of these individuals should be shot (you know who you are). But many others volunteered elaborate and thoughtful criticisms that went well beyond the call of duty. Their anonymous service is an inspiration.

Through its main health granting agency, Canada "been very very good to me." I thank the Canadian Institutes of Health Research for supporting this work with various grants and awards, including the Maud Menten New Investigator Prize, a CIHR New Investigator Award (Ethics in Translational Research: Navigating the Interface between the Bench and Clinic, MSH 87725), and several operating grants (States of Mind: Emerging Issues in Neuroethics, NNF 80045; Therapeutic Hopes and Ethical Concerns: Clinical Research in the Neurosciences, MOP 77670; Investigators as Inventors: An Empirical Study of Patent Holding and Ethics in Human Gene Transfer Research, MOP 79288; Advancing the Ethics of Clinical Trials: Enhancing Participant Protection and Scientific Rigour and a New Investigator Award, MOP 68835). This funding has allowed me to employ two resourceful and reliable research assistants over the years, David McLaughlin and Kat Duckworth.

This book emphasizes the role of social and technical networks for managing uncertainty and risk. What is true for novel medical interventions also applies for "risky" book projects like this. My cup runneth over with social infrastructure. First thanks go to my parents, Harold and Joyce Kimmelman, for enthusiasm and support. Harold also helped with the graphics and cover design. My wife, Sara Laimon, has been tireless in helping to maintain and restore order and morale throughout the book writing. She further offered very useful intellectual and stylistic feedback. I also thank several close friends for their care and feedback on various issues. They include: Cristiano Martello, Sean Hecht, Todd Krichmar, Naomi Schrag, and Laura Wolf-Powers. Finally, my daughters Rachel and Tamara had small hands in this project; I thank them for sustaining me with their humor, humanity, and reprieve.



Acknowledgments

Every effort has been made to ensure the accuracy of this book's content. None of the above acknowledgments should be interpreted as suggesting endorsement, sanction, confirmation, collusion, blandishment, complicity, or financial interest in this work or its author. Despite the use of high standards and care in writing this book, certain errors of analysis might have occurred. Money for harm or wages lost as a result of faulty analysis is not available. By reading this statement, you understand that I take full responsibility for any faults, foreseeable or unforeseeable, in the analysis.



Abbreviations

AAV adeno-associated virus

AAMC Association of American Medical Colleges

ADA adenosine deaminase

AHCJ Association of Health Care Journalists
ASGT American Society of Gene Therapy

CIOMS Council for International Organizations of Medical Sciences

CNS Central Nervous System

CRADA cooperative research and development agreement

CTEP cancer therapy evaluation program
CTSC Clinical and Translational Science Center
DARPA Defense Advanced Research Project Agency

DNA deoxyribonucleic acid

DSMB Data Safety Monitoring Board
ESGT European Society of Gene Therapy
FDA Food and Drug Administration
FH familial hypercholesterolemia
GAD glutamic acid decarboxylase

GIPAP Glivec International Patient Assistance Program

hESC human embryonic stem cell

HGTS Human Gene Therapy Subcommittee

HHS Health and Human Services
HIC high-income country

HIV human immunodeficiency virus
IBC Institutional Biosafety Committee
IHGT Institute for Human Gene Therapy

IND investigational new drug
IRB institutional review board
LCA Leber's congenital amaurosis
LMIC low-and middle-income country
MPS-VII mucopolysaccharidosis type VII

MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

NCI National Cancer Institute

NGVB National Gene Vector Biorepository
NGVL National Gene Vector Laboratories
NHF National Hemophilia Foundation

NHLBI National Heart Lung and Blood Institute

NIH National Institutes of Health

NUCDF National Urea Cycle Disorders Foundation

OBA Office of Biotechnology Activities
OTCD ornithine transcarbamylase deficiency



Abbreviations

PI principal investigator

RAC Recombinant DNA Advisory Committee

RNA ribonucleic acid

RNAi inhibitory ribonucleic acid

RT-PCR reverse transcriptase polymerase chain reaction

SCID severe combined immunodeficiency

siRNA small interfering RNA

STAIR Stroke Therapy Academic Industry Roundtable